Zhang C, Hou J, Li Z, Shen Q, Bai H, Chen L, Shen. PROTAR Vaccine 2.0 generates influenza vaccines by degrading multiple viral proteins. Nat Chem Biol. 2025 Jan 15
Manipulating viral protein stability using the cellular ubiquitin-proteasome system (UPS) represents a promising approach for developing live-attenuated vaccines. The first-generation proteolysis-targeting (PROTAR) vaccine had limitations, as it incorporates proteasome-targeting degrons (PTDs) at only the terminal ends of viral proteins, potentially restricting its broad application. Here we developed the next-generation PROTAR vaccine approach, referred to as PROTAR 2.0, which enabled flexible incorporation of PTDs at various genomic loci of influenza viruses, including internal regions and terminal ends. The PROTAR 2.0 influenza viruses maintained efficient replication in UPS-deficient cells for large-scale production but were attenuated by PTD-mediated proteasomal degradation of viral proteins in conventional cells. Incorporation of multiple PTDs into one virus generated optimized PROTAR 2.0 vaccine candidates. In animal models, PROTAR 2.0 vaccine candidates were highly attenuated and a single-dose intranasal immunization induced robust and broad immune responses that provided complete cross-reactive protection against both homologous and heterologous viral challenges.
See Also:
Latest articles in those days:
- Nonstructural Protein 1 of Influenza A (NS1A) Demonstrates Strain-Specific dsRNA Binding Capabilities 1 hours ago
- One-pot synthesized three-way junction based multiple strand displacement amplification for sensitive assay of H5N1 DNA 1 hours ago
- [preprint]The impact of influenza A H5N1 virus infection in dairy cows 3 hours ago
- Human Cases of Highly Pathogenic Avian Influenza A(H5N1) - California, September-December 2024 4 hours ago
- Immune history shapes human antibody responses to H5N1 influenza viruses 16 hours ago
[Go Top] [Close Window]